1 citations
,
August 2022 in “International journal of biological and chemical sciences” Iodine-deficient diets and antithyroid substances affected rat growth and behavior, but most adapted with positive weight gain.
July 2025 in “International Journal Of Literature And Languages” Cultural and national factors shape gender roles in advertising, highlighting the need for inclusive, gender-sensitive language.
September 2023 in “Jurnal MIPA (edisi elektronik)” Lime extract can be used to make a stable hair tonic with beneficial compounds.
June 2023 in “Aesthetic Plastic Surgery” The PRECISE scale helps estimate how many grafts are needed for hair transplant based on the severity of hair loss.
November 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” Certain medications and smaller pupil size increase the risk of intraoperative floppy iris syndrome during eye surgery.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
37 citations
,
January 2023 in “Ophthalmology and Therapy” Low-level red light therapy can shorten eye length in some myopic children.
November 2019 in “Neuro-oncology” Rind-based techniques can lower scalp radiation dose and reduce hair loss in brain cancer treatment.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
71 citations
,
March 2016 in “PubMed” Smaller particles improve drug delivery through the skin.
4 citations
,
April 2020 in “Dermatology practical & conceptual” Reflectance confocal microscopy is useful for diagnosing and monitoring skin diseases, but it has limitations and requires expertise for correct use.
January 2026 in “Dermatologic Therapy” Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.
76 citations
,
January 1998 in “Mammalian Genome”
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
Proretinal nanoparticles are a safe and effective way to deliver retinal to the skin.
11 citations
,
August 2014 in “PLoS ONE” GFRα2 is essential for controlling neuron size but not for target innervation in certain sensory neurons.
263 citations
,
February 2011 in “Journal of Controlled Release” Medium-sized particles penetrate hair follicles better than smaller or larger ones, which could improve delivery of skin treatments.
July 2023 in “SKIN The Journal of Cutaneous Medicine” Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
July 2025 in “Communications Biology” Rat vibrissae structure relates to their sensory function.
40 citations
,
March 2019 in “Pharmaceutical development and technology” Smaller particles of the drug carrier penetrated skin better, with 300 nm size being best for targeting hair follicles.
August 2024 in “Case Reports in Ophthalmology” Older patients with new retinal lesions may have cancer, and local radiation might not stop it from spreading.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
April 2025 in “Experimental Eye Research” The Oat mouse model shows mild retinal degeneration, useful for testing treatments.
14 citations
,
March 2019 in “European journal of pharmaceutics and biopharmaceutics” Proretinal nanoparticles improve skin absorption and reduce irritation of topical retinoids.
September 2023 in “Journal of the American Academy of Dermatology”
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
1 citations
,
October 2025 in “Ophthalmology Science” Lower doses of topotecan are safe for eyes, but higher doses may harm the retina.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.